New approaches to the treatment of age-related brain disorders.
Two novel reversible enzyme inhibitors involved in monoamine metabolism are described. The novel and reversible inhibitors are the catechol-O-methyl-transferase (COMT) inhibitors, Ro 40-7592 (3,4-dihydroxy-4'-methyl-5-nitrobenzophenone), and the monoamine oxidase type-B (MAO-B) inhibitor, Ro 19-6327 (N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide HC1). These may be of special therapeutic benefit in Parkinson's and Alzheimer's diseases.
Pharma Research Department, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
M
M
Da Prada
D000375:Aging; D000544:Alzheimer Disease / Q000188:drug therapy*; D001545:Benserazide / Q000627:therapeutic use; D001577:Benzophenones / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D004338:Drug Combinations; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy*; D010848:Picolinic Acids / Q000627:therapeutic use*; D000077867:Tolcapone
D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D008996:Monoamine Oxidase Inhibitors; D009596:Nitrophenols; D010848:Picolinic Acids; C005177:benserazide, levodopa drug combination; C059303:lazabemide; D007980:Levodopa; D001545:Benserazide; D000077867:Tolcapone